chartexchange

Rani Therapeutics Reports Q3 2026 Revenue of $1.7 Million, EPS of -$0.04 Beat Estimates

GuruFocus | Nov 9, 2026 5:31 PM EST

FDA Emerging Technology Program Acceptance and Partnership Revenue Shape a Transitional Quarter for the Clinical-Stage Biotech Related Stocks: RANI ,

Read original article